Open AccessAmyloid‐associated increases in longitudinal report of subjective cognitive complaints
Author(s) -
Amariglio Rebecca E.,
Buckley Rachel F.,
Mormino Elizabeth C.,
Marshall Gad A.,
Johnson Keith A.,
Rentz Dorene M.,
Sperling Reisa A.
Publication year - 2018
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2018.08.005
Subject(s) - cognitive decline , neuropsychology , longitudinal study , cohort , cognition , pittsburgh compound b , medicine , gerontology , effects of sleep deprivation on cognitive performance , positron emission tomography , amyloid (mycology) , psychology , neuropsychological test , clinical psychology , dementia , psychiatry , pathology , cognitive impairment , nuclear medicine , disease
To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community‐dwelling individuals, were followed longitudinally (4.27 ± 1.35 years) with annual subjective memory questionnaires and neuropsychological assessment. 11 C Pittsburgh compound‐B positron emission tomography was used to measure cortical amyloid and to classify status (Aβ+/Aβ−) at baseline. Results Higher baseline SCC predicted more rapid cognitive decline on neuropsychological measures among those with elevated amyloid (t = −2.18, P < .0001). In addition, longitudinal report of SCC significantly increased over time, with SCC progression most pronounced among Aβ+ individuals (t = 2.24, P = .0005). Discussion SCC may inform risk for future cognitive decline and track progression of self‐perceived decline, particularly in those along the AD trajectory, providing potentially important indicators of clinical meaningfulness in AD prevention trials.